Vertex Pharmaceuticals — Q2 2022 Form 10-Q
Business context and period: Unaudited results for the quarter and six months ended June 30, 2022. Vertex operates in pharmaceuticals, with revenue primarily from cystic fibrosis (CF) medicines. TRIKAFTA/KAFTRIO was the principal growth driver.
Financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $2,196.2m (+22%) | $1,793.4m | $4,293.7m (+22%) | $3,517.7m |
| Operating income (loss) | $1,106.3m | $(37.9)m | $2,147.2m | $849.9m |
| Net income | $810.5m | $67.0m | $1,572.6m | $720.1m |
| Diluted EPS | $3.13 | $0.26 | $6.09 | $2.75 |
| Operating cash flow | — | $2,096.0m | $721.3m |
Q2 gross margin was approximately 88% (product revenue less cost of sales); operating margin was approximately 50%. Six-month operating margin was approximately 50%. Cost of sales was 12% of product revenue in Q2, versus 13% a year earlier.
Revenue mix: Q2 TRIKAFTA/KAFTRIO revenue was $1,893.2m, up 51%. U.S. product revenue rose 13% to $1,415.1m; ex-U.S. revenue rose 46% to $781.1m. Revenue declines in SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO were attributed primarily to patients switching to TRIKAFTA/KAFTRIO.
Liquidity and debt: Cash, cash equivalents and marketable securities totaled $9.25bn at June 30, up 23% from year-end; working capital was $8.95bn. Operating cash flow was $2.10bn; investing cash use was $112.5m and financing cash use was $47.7m. Revolving facilities were undrawn; the company reported $2.5bn of available capacity at quarter-end and compliance with covenants. Balance-sheet finance lease liabilities were $482.3m current/long-term combined as reported in the filing’s long-term finance lease line; long-term finance lease liabilities were $482.3m. No conventional borrowings were reported as drawn.
Material changes and unusual items
- Revenue growth reflected international launches and U.S. performance of TRIKAFTA/KAFTRIO, including the pediatric expansion.
- Net income increased substantially versus Q2 2021, when Vertex recorded a $900m CRISPR collaboration upfront payment as acquired in-process R&D. Q2 2022 acquired in-process R&D was $61.9m, primarily the $60m Catalyst asset acquisition payment.
- R&D expense increased 34% in Q2 to $600.1m, principally with advancing clinical programs; SG&A rose 11% to $215.3m.
- Other expense, net was $78.1m in Q2, largely reflecting unrealized losses on strategic equity investments. Six-month other expense was $150.9m.
- A $49.2m Q2 reduction in contingent-consideration expense reflected revised scope of certain acquired gene-editing programs. Vertex also recorded a $13m impairment of an in-process R&D intangible asset related to revised program scope.
Outlook, commentary and risks
- Management said existing cash and expected product-sale cash flows should fund operations for at least the next 12 months. No numerical revenue or earnings guidance is stated in the supplied filing text.
- Near-term milestones included expected late-2022 global filings for TRIKAFTA/KAFTRIO in children aged 2–5; exa-cel regulatory submissions in Europe and the U.K. by year-end 2022; and planned Phase 3 acute-pain development of VX-548 in Q4 2022. These are forward-looking expectations, not assured outcomes.
- Management cited clinical, regulatory, reimbursement, manufacturing and supply-chain execution as important uncertainties. Development costs and timelines are difficult to predict, and trial results may be adverse or interpreted differently.
- COVID-19 had not materially affected supply or medicine demand as of the filing; the company continued monitoring effects on trials, operations and resources.
- Subsequent events: in July 2022 Vertex agreed to acquire ViaCyte for approximately $320m cash and entered a Verve collaboration, paying $25m upfront and purchasing $35m of Verve stock. It also replaced its $500m revolving facility with a facility maturing in July 2027; the $2bn facility was due to mature in September 2022.
Important facts for investors to verify
- Whether TRIKAFTA/KAFTRIO growth and international reimbursement access continue, and how switching affects older CF products.
- Clinical data, regulatory timelines and commercial potential for exa-cel, VX-548, inaxaplin and the company’s type 1 diabetes programs.
- Progress and final cash impact of the ViaCyte acquisition, Verve collaboration and other business-development commitments.
- Volatility in strategic-investment valuations, contingent consideration and associated impairment judgments.
- Availability and terms of credit facilities, including the September 2022 maturity of the $2bn facility and any subsequent refinancing or repayment.
- Cash-tax effects of required R&D amortization and execution of the remaining $499.7m share-repurchase authorization.